Author Archives: truemeds

Sparsentan is an innovative dual-acting therapeutic that targets both the endothelin and renin–angiotensin systems, offering a novel approach to treating proteinuric kidney diseases such as IgA nephropathy and focal segmental glomerulosclerosis. By simultaneously reducing intraglomerular pressure and inhibiting pro-fibrotic signaling, sparsentan has demonstrated superior proteinuria reduction compared to conventional therapies in clinical trials. While its […]

Icotrokinra is an emerging selective TYK2 inhibitor developed for the treatment of immune-mediated inflammatory diseases such as psoriasis. By specifically targeting TYK2 within the JAK-STAT pathway, it modulates key cytokines including IL-12 and IL-23 while minimizing off-target effects associated with broader JAK inhibition. Early clinical data indicate promising efficacy and a favorable safety profile. Positioned […]

Venetoclax is a first-in-class, selective BCL-2 inhibitor that has redefined apoptosis-targeted therapy in hematologic malignancies. By restoring mitochondrial-mediated cell death, it demonstrates strong efficacy in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), particularly in combination regimens. Despite its clinical success, resistance mechanisms such as MCL-1 upregulation and BCL-2 mutations remain challenges. Ongoing research […]

PA-915 is an emerging experimental compound that has attracted attention as a potential next-generation rapid-acting antidepressant. PTSD Preclinical studies suggest that PA-915 may produce fast and sustained antidepressant-like effects without the dissociative or hallucinogenic side effects linked to ketamine and psychedelics. Introduction: The Search for Better Mental Health Treatments Depression and anxiety disorders remain among […]

NEO-811 is a first-in-class molecular glue degrader developed to target ARNT (HIF-1β), a critical component of the hypoxia-inducible factor signaling pathway in clear cell renal cell carcinoma (ccRCC). By promoting selective ARNT degradation through cereblon-mediated ubiquitination, NEO-811 aims to suppress tumor-promoting HIF activity more effectively than conventional inhibitors. This innovative targeted protein degradation strategy may […]

AZD8359 is an investigational CD8-guided T-cell-engaging antibody developed for prostate cancer research. By targeting STEAP2, a prostate-associated tumor antigen, and engaging T-cell activation through CD3 and CD8-directed mechanisms, AZD8359 represents a next-generation immunotherapy strategy for metastatic prostate cancer, including metastatic castration-resistant prostate cancer. Its trispecific design aims to redirect cytotoxic T cells toward STEAP2-positive tumor […]

TNG961 is an investigational oral molecular glue degrader designed to selectively degrade HBS1L in FOCAD-deficient cancer cells. By recruiting HBS1L to the CRBN-mediated protein degradation system, TNG961 disrupts the HBS1L/PELO ribosome rescue pathway and may expose a synthetic-lethal vulnerability in tumors with FOCAD loss. Preclinical research suggests potential relevance for cancers carrying 9p21-region deletions, including […]

EPI-326 is an investigational tissue-selective EGFR degrader developed by EpiBiologics for EGFR-driven solid tumors, including EGFR-mutant NSCLC and HNSCC. Learn how this bispecific antibody may reshape targeted oncology. Introduction: Why EGFR Still Matters in Cancer Therapy Epidermal growth factor receptor, commonly known as EGFR, has been one of the most important targets in precision oncology for […]

ECI830 is an investigational, selective CDK2 inhibitor attracting attention in cancer research for its role in cell cycle regulation. By targeting CDK2 activity, ECI830 may help researchers explore tumor proliferation, cyclin E/CDK2 signaling, and therapy resistance mechanisms. It is especially relevant to studies involving HR+/HER2− breast cancer and CCNE1-amplified solid tumors, where abnormal cell cycle […]